The VEGF pathway in lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1169-1181

  Alevizakos, Michalis ^a   Kaltsas, Serafim ^a   Syrigos, Konstantinos N ^a,b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Anti angiogenic; Cancer; Carcinogenesis; Lung; Therapy; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; PROTEIN KINASE INHIBITOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL ADENOMA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DNA REPLICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ESOPHAGUS CANCER; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTRADUCTAL CARCINOMA; KIDNEY CARCINOMA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CANCER; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84890367084     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2298-3     Document Type: Review

References (94)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
2. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B (2011) Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol 62(5):444-455
3. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudła B (2011) Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology. Endokrynol Pol 62(5):456-464
4. Larsen JE, Cascone T, Gerber DE et al (2011) Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 17(6):512-527
5. Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985
6. Vempati P, Mac Gabhann F, Popel AS (2010) Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS One 5(7):e11860
7. Ho QT, Kuo CJ (2007) Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39(7-8):1349-1357
8. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581-611
9. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH (2012) Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 31(1-2):143-162
10. Iozzo RV, San Antonio JD (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108(3):349-355
11. Dong F, Ha XQ (2010) Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy. Chin Med J (Engl) 123(17):2454-2460
12. Potente M, Gerhardt H, Carmeliet P (2011) Basic and therapeutic aspects of angiogenesis. Cell 146(6):873-887
13. Grunewald M, Avraham I, Dor Y et al (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1):175-189
14. Melero-Martin JM, Dudley AC (2011) Concise review: vascular stem cells and tumor angiogenesis. Stem Cells 29(2):163-168
15. Gadgeel SM (2012) Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 13(2):96-106
16. Goel S, Duda DG, Xu L et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071-1121
17. Korpanty G, Smyth E, Sullivan LA et al (2010) Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) 235(1):3-9
18. de Mello RA, Costa BM, Reis RM, Hespanhol V (2012) Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat Anticancer Drug Discov 7(1):118-131
19. Chung AS, Lee J, Ferrara N (2010) Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10(7):505-514
20. Lichtenberger BM, Tan PK, Niederleithner H et al (2010) Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 140(2):268-279
21. Raica M, Cimpean AM, Ribatti D (2009) Angiogenesis in pre-malignant conditions. Eur J Cancer 45(11):1924-1934
22. Des Guetz G, Uzzan B, Nicolas P et al (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94(12):1823-1832
23. Kut C, Mac Gabhann F, Popel AS (2007) Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97(7):978-985
24. Kaio E, Tanaka S, Kitadai Y et al (2003) Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 64(1):61-73
25. Galfrascoli E, Piva S, Cinquini M et al (2011) Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 43(4):286-294
26. Gaya A, Tse V (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 38(5):484-493
27. Vermeulen PB, van Golen KL, Dirix LY (2010) Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 116(11 Suppl):2748-2754
28. Fox SB, Generali DG, Harris AL (2007) Breast tumour angiogenesis. Breast Cancer Res 9(6):216
29. Wicki A, Rochlitz C (2012) Targeted therapies in breast cancer. Swiss Med Wkly 142:w13550
30. Sakamoto S, Ryan AJ, Kyprianou N (2008) Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 103(3):691-708
31. Vermeulen PB, van Golen KL, Dirix LY (2010) Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 116(11 Suppl):2748-2754
32. Niu YN, Xia SJ (2009) Stroma-epithelium crosstalk in prostate cancer. Asian J Androl 11(1):28-35
33. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104(9):1440-1451
34. Li L, Kaelin WG Jr (2011) New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 25(4):667-686
35. Singer EA, Gupta GN, Srinivasan R (2012) Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol 24(3):284-290
36. Kim WY, Lee HY (2009) Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J 276(17):4653-4664
37. Gerstner ER, Batchelor TT (2012) Antiangiogenic therapy for glioblastoma. Cancer J 18(1):45-50
38. Cappetta A, Lonardi S, Pastorelli D et al (2012) Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Crit Rev Oncol Hematol 81(1):38-48
39. De Vita F, Giuliani F, Silvestris N et al (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets 16(Suppl 2):S29-S34
40. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH (2012) Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 31(1-2):143-162
41. Kim A, Ueda Y, Naka T, Enomoto T (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31:14
42. Schoenleber SJ, Kurtz DM, Talwalkar JA et al (2009) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100(9):1385-1392
43. Cervello M, McCubrey JA, Cusimano A et al (2012) Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3(3):236-260
44. Yang X, Flaig TW (2010) Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int Braz J Urol 36(3):273-282
45. Black PC (2012) Molecular signaling and the role of targeted therapies in bladder cancer. Minerva Urol Nefrol 64(1):7-17
46. Medinger M, Fischer N, Tzankov A (2010) Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol 2010:729725
47. Schmidt T, Carmeliet P (2011) Angiogenesis: a target in solid tumors, also in leukemia? Hematol Am Soc Hematol Educ Program 2011:1-8
48. Keefe SM, Cohen MA, Brose MS (2010) Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 16(3):778-783
49. Schlumberger M, Sherman SI (2012) Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166(1):5-11
50. Marneros AG (2009) Tumor angiogenesis in melanoma. Hematol Oncol Clin North Am 23(3):431-446, vii-viii
51. Mangana J, Levesque MP, Karpova MB, Dummer R (2012) Sorafenib in melanoma. Expert Opin Investig Drugs 21(4):557-568
52. Aldoss IT, Ganti AK (2009) Targeted therapy for squamous cell carcinoma of the head and neck. J Egypt Natl Canc Inst 21(2):157-166
53. Karatzanis AD, Koudounarakis E, Papadakis I, Velegrakis G (2012) Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. Eur Arch Otorhinolaryngol 269(3):731-737
54. Raza S, Kornblum N, Kancharla VP et al (2011) Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. Recent Pat Anticancer Drug Discov 6(2):246-257
55. Voelkel NF, Vandivier RW, Tuder RM (2006) Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 290:L209-L221
56. Bonnesen B, Pappot H, Holmstav J, Skov BG (2009) Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 66(3):314-318
57. Du L, Pertsemlidis A (2010) microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev 29(1):109-122
58. Liu B, Peng XC, Zheng XL et al (2009) MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 66(2):169-175
59. Lee JM, Yanagawa J, Peebles KA et al (2008) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66(3):208-217
60. Belani CP, Goss G, Blumenschein G Jr (2012) Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 38(3):173-184
61. Pennell NA, Lynch TJ Jr (2009) Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4):399-411
62. Zhan P, Wang J, Lv XJ et al (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094-1103
63. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23(14):3243-3256
64. Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51(2):143-158
65. Yuan A, Yu CJ, Chen WJ et al (2000) Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89(6):475-483
66. Salgia R (2011) Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 117(17):3889-3899
67. Jain L, Vargo CA, Danesi R et al (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8(9):2496-2508
68. Shang B, Cao Z, Zhou Q (2012) Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives. Front Med 6(1):67-78
69. Kubota Y (2012) Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 61(2):47-56
70. Blumenschein GR Jr (2012) Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs 30(4):1802-1811
71. Gaya A, Tse V (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 38(5):484-493
72. Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72(8):1909-1914
73. Shibuya M (2008) Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 41(4):278-286
74. Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23(5):289-304
75. Bar J, Goss GD (2012) Tumor vasculature as a therapeutic target in non-small cell lung cancer. J Thorac Oncol 7(3):609-620
76. Jain RK, Duda DG, Willett CG et al (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6):327-338
77. Reinmuth N, Thomas M, Meister M, Schnabel PA, Kreuter M (2010) Current data on predictive markers for anti-angiogenic therapy in thoracic tumours. Eur Respir J 36(4):915-924
78. Yu L, Deng L, Li J et al (2013) The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 128(2):391-396
79. Kampen KR (2012) The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anticancer Drugs 23(4):347-354
80. Bando H, Weich HA, Brokelmann M et al (2005) Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 92(3):553-561
81. Liu L, Ma XL, Xiao ZL et al (2012) Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer Prev 13(7):3089-3097
82. Mineta H, Miura K, Ogino T et al (2000) Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 83(6):775-781
83. Sun L, Yu D, Sun S-Y et al (2013) Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers. Cell Biochem Biophys. doi: 10.1007/s12013-013-9729-y
84. Łuczyńska E, Gasińska A, Wilk W (2013) Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer. Pol J Pathol 64(1):33-38
85. Hu-Lowe DD, Zou HY, Grazzini ML et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14(22):7272-7283
86. Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65(10):4389-4400
87. Polverino A, Coxon A, Starnes C et al (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66(17):8715-8721
88. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109
89. Sun L, Liang C, Shirazian S et al (2003) Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole- 3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46(7):1116-1119
90. Wedge SR, Ogilvie DJ, Dukes M et al (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62(16):4645-4655
91. Lambrechts D, Lenz HJ, de Haas S et al (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31(9):1219-1230. doi: 10.1200/JCO.2012.46.2762 (Epub 2013 Feb 11)
92. Vaziri SA, Kim J, Ganapathi MK, Ganapathi R (2010) Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep. 12(2):102-108
93. Lambrechts D, Claes B, Delmar P et al (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13(7):724-733
94. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672-4678